Simultaneous inhibition of HSP90 and BCL-2 offers a strategy to target these interconnected mechanisms, destabilize oncogenic proteins, and promote apoptosis in resistant breast cancer cells. The gene discussed is HSP90AA1; the disease is breast carcinoma.